JP2016034981A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016034981A5 JP2016034981A5 JP2015236828A JP2015236828A JP2016034981A5 JP 2016034981 A5 JP2016034981 A5 JP 2016034981A5 JP 2015236828 A JP2015236828 A JP 2015236828A JP 2015236828 A JP2015236828 A JP 2015236828A JP 2016034981 A5 JP2016034981 A5 JP 2016034981A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- seq
- isolated nucleic
- nucleotide sequence
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2009/004659 WO2010019261A1 (en) | 2008-08-14 | 2009-08-13 | Use of gdf traps to increase red blood cell levels |
| US12/583,177 US8058229B2 (en) | 2008-08-14 | 2009-08-13 | Method of increasing red blood cell levels or treating anemia in a patient |
| US12/583,177 | 2009-08-13 | ||
| USPCT/US2009/004659 | 2009-08-13 | ||
| US30590110P | 2010-02-18 | 2010-02-18 | |
| US61/305,901 | 2010-02-18 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012524910A Division JP5909446B2 (ja) | 2009-08-13 | 2010-08-13 | 赤血球レベルを増大させるための、ｇｄｆトラップとエリスロポエチン受容体活性化因子とを組み合わせた使用 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018153528A Division JP6860533B2 (ja) | 2009-08-13 | 2018-08-17 | 赤血球レベルを増大させるための、ｇｄｆトラップとエリスロポエチン受容体活性化因子とを組み合わせた使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016034981A JP2016034981A (ja) | 2016-03-17 |
| JP2016034981A5 true JP2016034981A5 (https=) | 2016-06-30 |
Family
ID=43586530
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012524910A Active JP5909446B2 (ja) | 2009-08-13 | 2010-08-13 | 赤血球レベルを増大させるための、ｇｄｆトラップとエリスロポエチン受容体活性化因子とを組み合わせた使用 |
| JP2015236828A Withdrawn JP2016034981A (ja) | 2009-08-13 | 2015-12-03 | 赤血球レベルを増大させるための、ｇｄｆトラップとエリスロポエチン受容体活性化因子とを組み合わせた使用 |
| JP2018153528A Active JP6860533B2 (ja) | 2009-08-13 | 2018-08-17 | 赤血球レベルを増大させるための、ｇｄｆトラップとエリスロポエチン受容体活性化因子とを組み合わせた使用 |
| JP2020163806A Pending JP2020203953A (ja) | 2009-08-13 | 2020-09-29 | 赤血球レベルを増大させるための、ｇｄｆトラップとエリスロポエチン受容体活性化因子とを組み合わせた使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012524910A Active JP5909446B2 (ja) | 2009-08-13 | 2010-08-13 | 赤血球レベルを増大させるための、ｇｄｆトラップとエリスロポエチン受容体活性化因子とを組み合わせた使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018153528A Active JP6860533B2 (ja) | 2009-08-13 | 2018-08-17 | 赤血球レベルを増大させるための、ｇｄｆトラップとエリスロポエチン受容体活性化因子とを組み合わせた使用 |
| JP2020163806A Pending JP2020203953A (ja) | 2009-08-13 | 2020-09-29 | 赤血球レベルを増大させるための、ｇｄｆトラップとエリスロポエチン受容体活性化因子とを組み合わせた使用 |
Country Status (13)
| Country | Link |
|---|---|
| EP (3) | EP3117829B1 (https=) |
| JP (4) | JP5909446B2 (https=) |
| KR (5) | KR20180085825A (https=) |
| CN (7) | CN105561295B (https=) |
| AU (1) | AU2010282361B2 (https=) |
| BR (2) | BR112012003232B1 (https=) |
| CA (1) | CA2770822C (https=) |
| ES (2) | ES2796121T3 (https=) |
| IL (6) | IL287990B (https=) |
| MX (2) | MX2012001916A (https=) |
| NZ (3) | NZ623113A (https=) |
| RU (2) | RU2642302C1 (https=) |
| WO (1) | WO2011020045A1 (https=) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1771470B1 (en) | 2004-07-23 | 2013-06-26 | Acceleron Pharma Inc. | Actrii receptor polypeptides, methods and compositions |
| US8128933B2 (en) | 2005-11-23 | 2012-03-06 | Acceleron Pharma, Inc. | Method of promoting bone growth by an anti-activin B antibody |
| KR20190006086A (ko) | 2005-11-23 | 2019-01-16 | 악셀레론 파마 인코포레이티드 | 액티빈-ａｃｔｒⅱａ 길항제 및 골 성장을 촉진하기 위한 이들의 용도 |
| US8895016B2 (en) | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
| EP2111229B1 (en) | 2007-02-01 | 2013-04-10 | Acceleron Pharma, Inc. | Pharmaceutical compositions comprising Activin-ActRIIA antagonists for use in preventing or treating breast cancer metastasis or breast cancer related bone loss |
| TWI782836B (zh) | 2007-02-02 | 2022-11-01 | 美商艾瑟勒朗法瑪公司 | 衍生自ActRIIB的變體與其用途 |
| ES2756725T3 (es) | 2007-02-09 | 2020-04-27 | Acceleron Pharma Inc | Composiciones farmacéuticas que comprenden antagonistas de Activina-ActRIIA |
| EP3243524A1 (en) | 2007-09-18 | 2017-11-15 | Acceleron Pharma Inc. | Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion |
| SMT202300222T1 (it) | 2008-08-14 | 2023-09-06 | Acceleron Pharma Inc | Trappole di gdf |
| US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
| US8138142B2 (en) | 2009-01-13 | 2012-03-20 | Acceleron Pharma Inc. | Methods for increasing adiponectin in a patient in need thereof |
| BRPI1010587A2 (pt) | 2009-06-08 | 2019-04-09 | Acceleron Pharma Inc. | métodos para aumentar adipócitos termogênicos |
| EP2440577A4 (en) | 2009-06-12 | 2013-01-23 | Acceleron Pharma Inc | SHORTEN ACTRIIB FC FUSION PROTEINS |
| JP6267425B2 (ja) | 2009-11-17 | 2018-01-24 | アクセルロン ファーマ， インコーポレイテッド | 筋ジストロフィー治療のためのユートロフィン誘導に関するａｃｔｒｉｉｂタンパク質およびその改変体およびその使用 |
| CN103298832A (zh) | 2010-11-08 | 2013-09-11 | 阿塞勒隆制药公司 | Actriia结合剂及其用途 |
| BR112014009528B1 (pt) * | 2011-10-17 | 2020-12-29 | Acceleron Pharma, Inc. | usos de polipeptídeos actriib para a fabricação de um medicamento para tratar eritropoiese ineficaz |
| US9809636B2 (en) | 2012-04-06 | 2017-11-07 | Acceleron Pharma Inc. | Methods for increasing red blood cell levels comprising administering BMP9 |
| AU2013334660B2 (en) * | 2012-10-24 | 2018-08-09 | Celgene Corporation | Methods for treating anemia |
| CN104968801B (zh) * | 2012-10-24 | 2021-06-15 | 细胞基因公司 | 用于治疗贫血症的生物标志物 |
| NZ707477A (en) | 2012-11-02 | 2019-09-27 | Celgene Corp | Activin-actrii antagonists and uses for treating bone and other disorders |
| MA39722A (fr) * | 2014-03-21 | 2021-06-02 | Acceleron Pharma Inc | Composition pour son utilisation dans une methode de traitement ou de prevention de l'anemie par l'inhibition de l'activine b et du gdf11 |
| WO2015192111A1 (en) | 2014-06-13 | 2015-12-17 | Acceleron Pharma, Inc. | Methods and compositions for treating ulcers |
| MA41052A (fr) * | 2014-10-09 | 2017-08-15 | Celgene Corp | Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii |
| US10603359B2 (en) | 2014-10-30 | 2020-03-31 | Acceleron Pharma Inc. | Methods and compositions using GDF15 polypeptides for increasing red blood cells |
| MA41119A (fr) * | 2014-12-03 | 2017-10-10 | Acceleron Pharma Inc | Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique |
| JP2018501307A (ja) | 2014-12-03 | 2018-01-18 | セルジーン コーポレイション | アクチビン−ＡｃｔＲＩＩアンタゴニスト及び貧血を治療するための使用 |
| EP3256148A1 (en) * | 2015-02-12 | 2017-12-20 | INSERM - Institut National de la Santé et de la Recherche Médicale | Methods for predicting the responsiveness of a patient affected with malignant hematological disease to chemotherapy treatment and methods of treatment of such disease |
| PT3286206T (pt) | 2015-04-22 | 2021-04-01 | Biogen Ma Inc | Novas proteínas híbridas bloqueadoras de ligando actriib para tratar doenças de desgaste muscular |
| MA42160A (fr) * | 2015-05-20 | 2018-03-28 | Maria Cappellini | Procédés de culture de cellules in vitro pour la beta-thalassemie a l'aide de pieges a ligands du recepteur de l'activine de type ii |
| US11123430B2 (en) | 2015-11-04 | 2021-09-21 | Acceleron Pharma Inc. | Methods for increasing red blood cell levels and treating ineffective erythropoiesis |
| CA3005975A1 (en) | 2015-11-23 | 2017-06-01 | Acceleron Pharma Inc. | Methods for treating eye disorders |
| AU2017222526A1 (en) * | 2016-02-22 | 2018-08-23 | Acceleron Pharma Inc. | ActRII antagonists for use in increasing immune activity |
| HRP20210694T1 (hr) | 2016-07-15 | 2021-09-17 | Acceleron Pharma, Inc. | Pripravci koji sadrže actriia polipeptide za uporabu za liječenje plućne hipertenzije |
| PL3490582T3 (pl) * | 2016-07-27 | 2024-09-23 | Acceleron Pharma Inc. | Kompozycje do zastosowania w leczeniu mielofibrozy |
| JP7280182B2 (ja) * | 2016-10-05 | 2023-05-23 | アクセルロン ファーマ インコーポレイテッド | バリアントＡｃｔＲＩＩＢタンパク質およびその使用 |
| JP2019529509A (ja) | 2016-10-05 | 2019-10-17 | アクセレロン ファーマ インコーポレーテッド | 腎臓疾患を治療するための組成物および方法 |
| JOP20190085A1 (ar) | 2016-10-20 | 2019-04-17 | Biogen Ma Inc | طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة |
| CN110430890B (zh) | 2016-11-10 | 2024-09-10 | 科乐斯疗法公司 | 激活素受体iia型变体及其使用方法 |
| HRP20241477T1 (hr) | 2017-06-14 | 2025-01-03 | Celgene Corporation | Postupci liječenja mijeloproliferativne neoplazme povezane s mijelofibrozom i anemijom |
| EP3706777B1 (en) | 2017-11-09 | 2024-05-22 | Keros Therapeutics, Inc. | Activin receptor type iia variants and methods of use thereof |
| IL320014A (en) | 2018-01-12 | 2025-06-01 | Keros Therapeutics Inc | Activin receptor type iib variants and methods of use thereof |
| JP7405772B2 (ja) | 2018-05-09 | 2023-12-26 | ケロス セラピューティクス インコーポレイテッド | アクチビンｉｉａ型受容体変異体および同変異体を含む医薬組成物 |
| RU2760324C1 (ru) | 2018-12-10 | 2021-11-24 | Елена Валентиновна Аршинцева | Новое применение полоксамера в качестве фармакологически активного вещества |
| IL296394A (en) | 2020-03-20 | 2022-11-01 | Keros Therapeutics Inc | Type ii activin receptor chimeras and methods of using them |
| WO2021189010A1 (en) | 2020-03-20 | 2021-09-23 | Keros Therapeutics, Inc. | Methods of using activin receptor type iib variants |
| CN111466337B (zh) * | 2020-05-19 | 2022-04-19 | 山东大学齐鲁医院 | 一种腹主动脉瘤动物模型及其构建方法 |
| US12186370B1 (en) | 2020-11-05 | 2025-01-07 | Celgene Corporation | ACTRIIB ligand trap compositions and uses thereof |
| CN115317589B (zh) * | 2022-09-05 | 2024-12-13 | 中国海洋大学 | 脯氨酰羟化酶抑制剂及其应用 |
| CN119198238A (zh) * | 2024-09-18 | 2024-12-27 | 广东省安家医健健康管理有限公司 | 一种地中海贫血检测系统及试剂盒 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1265208A (en) | 1915-09-07 | 1918-05-07 | Edward C Kahn | Liquid-fuel burner. |
| AU597574B2 (en) | 1986-03-07 | 1990-06-07 | Massachusetts Institute Of Technology | Method for enhancing glycoprotein stability |
| US5080891A (en) | 1987-08-03 | 1992-01-14 | Ddi Pharmaceuticals, Inc. | Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols |
| WO1990008822A1 (en) | 1989-02-03 | 1990-08-09 | Genetics Institute, Inc. | Erythropoietin receptor |
| US5677196A (en) | 1993-05-18 | 1997-10-14 | University Of Utah Research Foundation | Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays |
| US5525490A (en) | 1994-03-29 | 1996-06-11 | Onyx Pharmaceuticals, Inc. | Reverse two-hybrid method |
| US5885574A (en) | 1994-07-26 | 1999-03-23 | Amgen Inc. | Antibodies which activate an erythropoietin receptor |
| US5814565A (en) | 1995-02-23 | 1998-09-29 | University Of Utah Research Foundation | Integrated optic waveguide immunosensor |
| DE69636866D1 (en) | 1995-04-11 | 2007-03-15 | Gen Hospital Corp | Reverse "two-hybrid"-systeme |
| AU772694B2 (en) | 1999-01-21 | 2004-05-06 | Metamorphix International, Inc. | Growth differentiation factor inhibitors and uses therefor |
| PL219131B1 (pl) * | 2000-05-15 | 2015-03-31 | Hoffmann La Roche | Ciekła kompozycja farmaceutyczna, sposób jej wytwarzania oraz jej zastosowanie |
| US7087224B2 (en) * | 2000-10-31 | 2006-08-08 | Amgen Inc. | Method of treating anemia by administering IL-1ra |
| CN102552263A (zh) * | 2001-12-06 | 2012-07-11 | 法布罗根股份有限公司 | 提高内源性红细胞生成素(epo)的方法 |
| DE10234192B4 (de) * | 2002-07-26 | 2009-11-26 | Epoplus Gmbh Co.Kg | Verwendung von Erythropoetin |
| DK1592416T3 (da) * | 2003-02-07 | 2009-04-20 | Prometic Biosciences Inc | Fedtsyrer med middel kædelængde, glycerider og analoger som stimulatorer af erythropoiesis |
| GB0304424D0 (en) * | 2003-02-26 | 2003-04-02 | Glaxosmithkline Biolog Sa | Novel compounds |
| EP1771470B1 (en) | 2004-07-23 | 2013-06-26 | Acceleron Pharma Inc. | Actrii receptor polypeptides, methods and compositions |
| BRPI0518728A2 (pt) * | 2004-12-09 | 2008-12-02 | Univ Pittsburgh | vacinas para a resposta rÁpida À pandemia de gripe aviÁria |
| JPWO2006115274A1 (ja) * | 2005-04-26 | 2008-12-18 | 味の素株式会社 | 骨髄赤血球前駆細胞分化促進剤 |
| WO2007042169A2 (en) * | 2005-10-07 | 2007-04-19 | Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa | Matrix metalloproteinase 11 vaccine |
| US8067562B2 (en) * | 2005-11-01 | 2011-11-29 | Amgen Inc. | Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1 |
| WO2008073292A2 (en) * | 2006-12-08 | 2008-06-19 | Caritas St. Elizabeth's Medical Center Of Boston, Inc. | Method for protecting renal tubular epithelial cells from radiocontrast nephro parhy (rcn) |
| DK2124999T3 (da) * | 2006-12-18 | 2013-01-14 | Acceleron Pharma Inc | Activin-actrii antagonister og anvendelser til behandling af anæmi |
| TWI782836B (zh) * | 2007-02-02 | 2022-11-01 | 美商艾瑟勒朗法瑪公司 | 衍生自ActRIIB的變體與其用途 |
| JP5773868B2 (ja) * | 2008-06-26 | 2015-09-02 | アクセルロン ファーマ， インコーポレイテッド | アクチビン−ＡｃｔＲＩＩａのアンタゴニストおよび赤血球レベルを高めるためのその使用 |
| SMT202300222T1 (it) * | 2008-08-14 | 2023-09-06 | Acceleron Pharma Inc | Trappole di gdf |
-
2010
- 2010-08-13 KR KR1020187020803A patent/KR20180085825A/ko not_active Ceased
- 2010-08-13 CA CA2770822A patent/CA2770822C/en active Active
- 2010-08-13 NZ NZ623113A patent/NZ623113A/en unknown
- 2010-08-13 WO PCT/US2010/045509 patent/WO2011020045A1/en not_active Ceased
- 2010-08-13 BR BR112012003232-1A patent/BR112012003232B1/pt active IP Right Grant
- 2010-08-13 NZ NZ598348A patent/NZ598348A/en unknown
- 2010-08-13 IL IL287990A patent/IL287990B/en unknown
- 2010-08-13 EP EP16186033.3A patent/EP3117829B1/en active Active
- 2010-08-13 ES ES10808838T patent/ES2796121T3/es active Active
- 2010-08-13 EP EP10808838.6A patent/EP2464369B1/en active Active
- 2010-08-13 ES ES16186033T patent/ES2844123T3/es active Active
- 2010-08-13 KR KR1020127004678A patent/KR101882521B1/ko active Active
- 2010-08-13 RU RU2016123808A patent/RU2642302C1/ru active
- 2010-08-13 KR KR1020197027722A patent/KR102170682B1/ko active Active
- 2010-08-13 CN CN201510979350.1A patent/CN105561295B/zh active Active
- 2010-08-13 CN CN201080045618.XA patent/CN102655872B/zh active Active
- 2010-08-13 BR BR122020019169-4A patent/BR122020019169B1/pt active IP Right Grant
- 2010-08-13 CN CN202110417494.3A patent/CN113082194B/zh active Active
- 2010-08-13 MX MX2012001916A patent/MX2012001916A/es active IP Right Grant
- 2010-08-13 NZ NZ712943A patent/NZ712943A/en unknown
- 2010-08-13 RU RU2012109393/10A patent/RU2592670C2/ru active
- 2010-08-13 EP EP20197940.8A patent/EP3838919A1/en not_active Withdrawn
- 2010-08-13 KR KR1020227045338A patent/KR102606494B1/ko active Active
- 2010-08-13 AU AU2010282361A patent/AU2010282361B2/en active Active
- 2010-08-13 KR KR1020207030283A patent/KR20200124322A/ko not_active Ceased
- 2010-08-13 CN CN202110421547.9A patent/CN113171442B/zh active Active
- 2010-08-13 JP JP2012524910A patent/JP5909446B2/ja active Active
- 2010-08-13 CN CN202110879546.9A patent/CN113577291A/zh active Pending
- 2010-08-13 CN CN201510979490.9A patent/CN105535938B/zh active Active
- 2010-08-13 CN CN201510979291.8A patent/CN105412908B/zh active Active
-
2012
- 2012-02-12 IL IL218052A patent/IL218052A/en active IP Right Grant
- 2012-02-13 MX MX2019010341A patent/MX2019010341A/es unknown
-
2015
- 2015-12-03 JP JP2015236828A patent/JP2016034981A/ja not_active Withdrawn
-
2017
- 2017-05-01 IL IL25204417A patent/IL252044B/en active IP Right Grant
- 2017-05-01 IL IL252046A patent/IL252046B/en active IP Right Grant
- 2017-05-01 IL IL252045A patent/IL252045B/en active IP Right Grant
-
2018
- 2018-08-17 JP JP2018153528A patent/JP6860533B2/ja active Active
-
2020
- 2020-07-05 IL IL275851A patent/IL275851B/en unknown
- 2020-09-29 JP JP2020163806A patent/JP2020203953A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016034981A5 (https=) | ||
| JP2016187361A5 (https=) | ||
| JP2018138049A5 (https=) | ||
| JP2014000092A5 (https=) | ||
| JP2017524380A5 (ja) | 腫瘍血管遮断剤であるポリペプチド、遺伝子、発現ベクター、腫瘍血管遮断剤の組成物、及び腫瘍血管遮断剤であるポリペプチドの調製方法 | |
| JP2015533791A5 (https=) | ||
| JP2017212998A5 (https=) | ||
| JP2016073298A5 (https=) | ||
| JP2015520178A5 (https=) | ||
| JP2015096070A5 (https=) | ||
| SA522433360B1 (ar) | L-أَسْباراجيناز مُعدل | |
| JP2018520997A5 (https=) | ||
| JP2014012022A5 (https=) | ||
| JP2016052331A5 (https=) | ||
| JP2013027391A5 (https=) | ||
| JP2010088434A5 (https=) | ||
| JP2014193147A5 (https=) | ||
| JP2017006120A5 (https=) | ||
| CN109937252A (zh) | 重组dna聚合酶 | |
| JP2015524403A5 (https=) | ||
| WO2014202622A3 (en) | Rasamsonia gene and use thereof | |
| WO2009024327A3 (en) | New proteins for use in human and animal staphylococcus infections | |
| CN109641937A (zh) | OsAO基因在提高水稻对水稻条纹病毒及水稻黑条矮缩病毒或其同科病毒抗性中的应用 | |
| JP2016503289A5 (https=) | ||
| EA201890351A1 (ru) | Рекомбинантный orf-вирусный вектор |